cilostazol has been researched along with Anterior Choroidal Artery Infarction in 40 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "Published animal data support the overall efficacy of cilostazol in reducing infarct volume and neurofunctional deficits in cerebral ischemia models and cerebral vasospasm in subarachnoid hemorrhage models." | 9.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 9.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| " Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge." | 9.15 | Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. ( Inoue, T; Mannoji, H; Nakamura, T; Nishimura, H; Ohta, M; Sayama, T; Suzuki, S; Takeshita, I, 2011) |
| "The antiplatelet drug cilostazol is efficacious for prevention of stroke recurrence compared with placebo." | 9.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 9.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "All RCTs investigating the effect of cilostazol on secondary prevention of ischemic stroke were obtained." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "This study investigated the impact of polymorphisms of metabolic enzymes on plasma concentrations of cilostazol and its metabolites, and the influence of the plasma concentrations and polymorphisms on the cardiovascular side effects in 30 patients with cerebral infarction." | 8.02 | Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction. ( Asahara, Y; Kagawa, Y; Kaneshiro, Y; Maeda, T; Murata, K; Urano, Y; Yamagata, K; Yamauchi, S; Yokoyama, T, 2021) |
| "Cilostazol is a selective inhibitor of phosphodiesterase type III that downregulates tenascin-C (TNC), a matricellular protein, which may cause delayed cerebral infarction after aneurysmal subarachnoid hemorrhage (SAH)." | 7.91 | Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. ( Goto, F; Hakozaki, K; Miura, Y; Nakatsuka, Y; Shiba, M; Suzuki, H; Suzuki, Y; Terashima, M; Toma, N; Yasuda, R, 2019) |
| " We compared changes in the occurrence of pneumonia between cilostazol (n = 127) and noncilostazol (n = 72) groups." | 7.88 | Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction. ( Arawaka, S; Kimura, F; Nakajima, H; Nakamura, Y; Unoda, K, 2018) |
| "A low platelet response to cilostazol determined by a new platelet assay was associated with the recurrence of thrombotic events in patients with cerebral infarction." | 7.88 | Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. ( Hato, T; Ikeda, Y; Kumon, Y; Yamanouchi, J; Yasukawa, M, 2018) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "This retrospective study examined the effectiveness of cilostazol in preventing aspiration pneumonia in patients with acute cerebral infarction." | 7.79 | Efficacy of cilostazol in preventing aspiration pneumonia in acute cerebral infarction. ( Maeshima, S; Osawa, A; Tanahashi, N, 2013) |
| "Our results suggest that patients treated with cilostazol before onset of stroke could have a lower risk of cerebral hemorrhage after thrombolytic therapy and might also have a longer therapeutic time window for thrombolysis." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "A Markov model was developed to calculate the health outcomes and associated costs for 65-year-old patients with cerebral infarction who were treated with 200 mg/day cilostazol or 81 mg/day aspirin." | 7.73 | Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. ( Inoue, T; Kobayashi, M; Uchiyama, S; Uetsuka, Y, 2006) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 7.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method." | 7.67 | Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. ( Katsube, T; Kitani, M; Kobayashi, S; Okada, K; Tsunematsu, T; Yamaguchi, S, 1985) |
| "The effects of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1H)-quinolinone (cilostazol, OPC-13013), acetylsalicylic acid (ASA) and ifenprodil on experimentally induced cerebral infarction were studied in anesthetized rabbits." | 7.67 | Effect of cilostazol on experimental cerebral infarction in rabbits. ( Kimura, Y; Nakase, H; Watanabe, K, 1986) |
| " Furthermore, we examined whether clinical outcomes were associated with the dosage of cilostazol (300 mg/day vs." | 6.82 | Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis. ( Awil, MA; Chen, X; Feng, Y; He, J; Hou, D; Liu, J; Tian, Y; Wang, C; Wang, Y, 2022) |
| "As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 6.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "Published animal data support the overall efficacy of cilostazol in reducing infarct volume and neurofunctional deficits in cerebral ischemia models and cerebral vasospasm in subarachnoid hemorrhage models." | 5.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 5.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| "Twelve patients with cerebral infarction (mean age 66." | 5.28 | Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication. ( Kobayashi, S; Okada, K; Tsunematsu, T; Yamashita, K, 1990) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 5.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| " Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge." | 5.15 | Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. ( Inoue, T; Mannoji, H; Nakamura, T; Nishimura, H; Ohta, M; Sayama, T; Suzuki, S; Takeshita, I, 2011) |
| "The antiplatelet drug cilostazol is efficacious for prevention of stroke recurrence compared with placebo." | 5.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| " Cilostazol is useful for the prevention of the recurrence of vascular events in patients with lacunar infarction, and is probably effective in high-risk patients with diabetes and/or hypertension." | 5.13 | Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. ( Fukuuchi, Y; Gotoh, F; Hirai, S; Itoh, E; Matsuda, T; Nishimaru, K; Ohashi, Y; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2008) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 5.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "All RCTs investigating the effect of cilostazol on secondary prevention of ischemic stroke were obtained." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "This study investigated the impact of polymorphisms of metabolic enzymes on plasma concentrations of cilostazol and its metabolites, and the influence of the plasma concentrations and polymorphisms on the cardiovascular side effects in 30 patients with cerebral infarction." | 4.02 | Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction. ( Asahara, Y; Kagawa, Y; Kaneshiro, Y; Maeda, T; Murata, K; Urano, Y; Yamagata, K; Yamauchi, S; Yokoyama, T, 2021) |
| "Cilostazol is a selective inhibitor of phosphodiesterase type III that downregulates tenascin-C (TNC), a matricellular protein, which may cause delayed cerebral infarction after aneurysmal subarachnoid hemorrhage (SAH)." | 3.91 | Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. ( Goto, F; Hakozaki, K; Miura, Y; Nakatsuka, Y; Shiba, M; Suzuki, H; Suzuki, Y; Terashima, M; Toma, N; Yasuda, R, 2019) |
| " We compared changes in the occurrence of pneumonia between cilostazol (n = 127) and noncilostazol (n = 72) groups." | 3.88 | Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction. ( Arawaka, S; Kimura, F; Nakajima, H; Nakamura, Y; Unoda, K, 2018) |
| "A low platelet response to cilostazol determined by a new platelet assay was associated with the recurrence of thrombotic events in patients with cerebral infarction." | 3.88 | Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. ( Hato, T; Ikeda, Y; Kumon, Y; Yamanouchi, J; Yasukawa, M, 2018) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "This retrospective study examined the effectiveness of cilostazol in preventing aspiration pneumonia in patients with acute cerebral infarction." | 3.79 | Efficacy of cilostazol in preventing aspiration pneumonia in acute cerebral infarction. ( Maeshima, S; Osawa, A; Tanahashi, N, 2013) |
| "Our results suggest that patients treated with cilostazol before onset of stroke could have a lower risk of cerebral hemorrhage after thrombolytic therapy and might also have a longer therapeutic time window for thrombolysis." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "A Markov model was developed to calculate the health outcomes and associated costs for 65-year-old patients with cerebral infarction who were treated with 200 mg/day cilostazol or 81 mg/day aspirin." | 3.73 | Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. ( Inoue, T; Kobayashi, M; Uchiyama, S; Uetsuka, Y, 2006) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 3.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "In order to find out the difference between cilostazol and ticlopidine hydrochloride in the cerebral vasodilating effect in the chronic stage of cerebral infarction, cerebral blood flows were measured while the patients were on ticlopidine hydrochloride and after ticlopidine hydrochloride was switched to cilostazol." | 3.70 | Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. ( Mochizuki, Y; Oishi, M; Satoh, Y; Shikata, E, 2000) |
| "The effects of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1H)-quinolinone (cilostazol, OPC-13013), acetylsalicylic acid (ASA) and ifenprodil on experimentally induced cerebral infarction were studied in anesthetized rabbits." | 3.67 | Effect of cilostazol on experimental cerebral infarction in rabbits. ( Kimura, Y; Nakase, H; Watanabe, K, 1986) |
| "The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method." | 3.67 | Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. ( Katsube, T; Kitani, M; Kobayashi, S; Okada, K; Tsunematsu, T; Yamaguchi, S, 1985) |
| " Furthermore, we examined whether clinical outcomes were associated with the dosage of cilostazol (300 mg/day vs." | 2.82 | Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis. ( Awil, MA; Chen, X; Feng, Y; He, J; Hou, D; Liu, J; Tian, Y; Wang, C; Wang, Y, 2022) |
| "As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 2.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "A part of familial Hirschsprung disease has genetic factors in common with cerebrovascular disease." | 1.51 | A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease. ( Abe, K; Hishikawa, N; Ohta, Y; Sasaki, R; Sato, K; Takemoto, M; Yamashita, T, 2019) |
| "Cerebral infarction is a major cause of death or decreasing activities of daily living." | 1.38 | Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol. ( Abe, K; Deguchi, K; Kawai, H; Kurata, T; Ohta, Y; Omote, Y; Tian, F; Yamashita, T, 2012) |
| "He was diagnosed as idiopathic cerebral infarction." | 1.35 | [Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. ( Ikegami, M; Matsuda, S; Miyashita, Y; Obara, S; Shimizu, M; Sugiyama, N; Takagi, S; Takizawa, S; Yokoyama, J, 2009) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 1.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| "Twelve patients with cerebral infarction (mean age 66." | 1.28 | Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication. ( Kobayashi, S; Okada, K; Tsunematsu, T; Yamashita, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 19 (47.50) | 24.3611 |
| 2020's | 8 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoyama, T | 1 |
| Yamauchi, S | 1 |
| Yamagata, K | 1 |
| Kaneshiro, Y | 1 |
| Urano, Y | 1 |
| Murata, K | 1 |
| Maeda, T | 1 |
| Asahara, Y | 1 |
| Kagawa, Y | 1 |
| Li, L | 1 |
| Fu, X | 1 |
| Qiu, H | 1 |
| Shi, P | 1 |
| Liu, J | 1 |
| He, J | 1 |
| Chen, X | 1 |
| Feng, Y | 1 |
| Wang, C | 1 |
| Awil, MA | 1 |
| Wang, Y | 1 |
| Tian, Y | 1 |
| Hou, D | 1 |
| Uchiyama, S | 3 |
| Toyoda, K | 1 |
| Okamura, S | 1 |
| Omae, K | 1 |
| Hoshino, H | 1 |
| Kimura, K | 2 |
| Kitagawa, K | 1 |
| Minematsu, K | 1 |
| Yamaguchi, T | 3 |
| Aspide, R | 3 |
| Castioni, CA | 3 |
| Qureshi, AI | 3 |
| Akhtar, IN | 3 |
| Ma, X | 3 |
| Lodhi, A | 3 |
| Bhatti, I | 3 |
| Beall, J | 3 |
| Broderick, JP | 3 |
| Cassarly, CN | 3 |
| Martin, RH | 3 |
| Sharma, R | 3 |
| Thakkar, M | 3 |
| Suarez, JI | 3 |
| Hankey, GJ | 1 |
| Saji, N | 1 |
| Tone, S | 1 |
| Murotani, K | 1 |
| Yagita, Y | 1 |
| Sakurai, T | 1 |
| Zhang, JJ | 1 |
| Liu, X | 1 |
| Nakamura, Y | 1 |
| Nakajima, H | 1 |
| Kimura, F | 1 |
| Unoda, K | 1 |
| Arawaka, S | 1 |
| Suzuki, H | 1 |
| Nakatsuka, Y | 1 |
| Yasuda, R | 1 |
| Shiba, M | 1 |
| Miura, Y | 1 |
| Terashima, M | 1 |
| Suzuki, Y | 1 |
| Hakozaki, K | 1 |
| Goto, F | 1 |
| Toma, N | 1 |
| Noma, K | 1 |
| Higashi, Y | 1 |
| Ikeda, Y | 1 |
| Yamanouchi, J | 1 |
| Kumon, Y | 1 |
| Yasukawa, M | 1 |
| Hato, T | 1 |
| Shan, T | 1 |
| Zhang, T | 1 |
| Qian, W | 1 |
| Ma, L | 1 |
| Li, H | 1 |
| You, C | 1 |
| Xie, X | 1 |
| Sato, K | 1 |
| Sasaki, R | 1 |
| Ohta, Y | 2 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 2 |
| Abe, K | 2 |
| Abe, A | 1 |
| Nishiyama, Y | 1 |
| Hagiwara, H | 1 |
| Okubo, S | 1 |
| Ueda, M | 1 |
| Katsura, K | 1 |
| Katayama, Y | 2 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Yamamoto, Y | 2 |
| Shi, L | 1 |
| Pu, J | 1 |
| Xu, L | 1 |
| Malaguit, J | 1 |
| Zhang, J | 1 |
| Chen, S | 1 |
| Shinohara, Y | 3 |
| Gotoh, F | 1 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 1 |
| Otomo, E | 1 |
| Itoh, E | 1 |
| Matsuda, T | 1 |
| Sawada, T | 2 |
| Nishimaru, K | 2 |
| Ohashi, Y | 2 |
| Sugiyama, N | 1 |
| Matsuda, S | 1 |
| Shimizu, M | 1 |
| Obara, S | 1 |
| Ikegami, M | 1 |
| Yokoyama, J | 1 |
| Miyashita, Y | 1 |
| Takizawa, S | 1 |
| Takagi, S | 1 |
| Nonaka, Y | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Yoshimoto, T | 1 |
| Shirasaka, T | 1 |
| Fujimoto, S | 1 |
| Yoshidumi, T | 1 |
| Yamauchi, T | 1 |
| Tokuda, K | 1 |
| Kaneko, S | 1 |
| Kashiwaba, T | 1 |
| Handa, S | 1 |
| Matsuoka, K | 1 |
| Tanahashi, N | 2 |
| Yamamoto, H | 1 |
| Genka, C | 1 |
| Kitagawa, Y | 1 |
| Kusuoka, H | 1 |
| Tsushima, M | 1 |
| Koretsune, Y | 1 |
| Hamada, C | 1 |
| Kono, K | 1 |
| Ito, Y | 1 |
| Miyazaki, Y | 1 |
| Yasumori, K | 1 |
| Yasaka, M | 1 |
| Okada, Y | 1 |
| Nagata, S | 1 |
| Suzuki, S | 1 |
| Sayama, T | 1 |
| Nakamura, T | 1 |
| Nishimura, H | 1 |
| Ohta, M | 1 |
| Inoue, T | 2 |
| Mannoji, H | 1 |
| Takeshita, I | 1 |
| Ohara, T | 1 |
| Nagakane, Y | 1 |
| Tanaka, E | 1 |
| Morii, F | 1 |
| Koizumi, T | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Tian, F | 1 |
| Kawai, H | 1 |
| Kurata, T | 1 |
| Osawa, A | 1 |
| Maeshima, S | 1 |
| Ishikawa, M | 1 |
| Kobayashi, M | 1 |
| Uetsuka, Y | 1 |
| Park, SY | 1 |
| Lee, JH | 1 |
| Kim, CD | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Lee, WS | 1 |
| Oishi, M | 1 |
| Mochizuki, Y | 1 |
| Shikata, E | 1 |
| Satoh, Y | 1 |
| Yamaya, M | 1 |
| Yanai, M | 1 |
| Ohrui, T | 1 |
| Arai, H | 1 |
| Sekizawa, K | 1 |
| Sasaki, H | 1 |
| Shinoda-Tagawa, T | 1 |
| Yamasaki, Y | 1 |
| Yoshida, S | 1 |
| Kajimoto, Y | 1 |
| Tsujino, T | 1 |
| Hakui, N | 1 |
| Matsumoto, M | 1 |
| Hori, M | 1 |
| Yamashita, K | 1 |
| Kobayashi, S | 2 |
| Okada, K | 2 |
| Tsunematsu, T | 2 |
| Watanabe, K | 1 |
| Nakase, H | 1 |
| Kimura, Y | 1 |
| Yamaguchi, S | 1 |
| Katsube, T | 1 |
| Kitani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin[NCT00234065] | Phase 4 | 2,800 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 13 |
| Aspirin | 13 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 138 |
| Aspirin | 186 |
The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 23 |
| Aspirin | 57 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 86 |
| Aspirin | 103 |
(NCT00234065)
Timeframe: From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 72 |
| Aspirin | 88 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 82 |
| Aspirin | 119 |
9 reviews available for cilostazol and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Treatment Outcome; | 2022 |
Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis.
Topics: Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Treatment Outcome; Vasospasm, Intr | 2022 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hema | 2018 |
Cilostazol for treatment of cerebral infarction.
Topics: Cerebral Infarction; Cilostazol; Humans; Platelet Aggregation Inhibitors | 2018 |
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Brain Ischemia; Cardiovascular Agents; Cerebral Infarction; Cilostazol; Humans; Intracranial Aneurys | 2020 |
[Concept, pathophysiology and treatment for branch atheromatous disease].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Clopidogrel; Contraindications; Drug Therapy, | 2014 |
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; | 2010 |
7 trials available for cilostazol and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Administration of cilostazol, an antiplatelet, to patients with acute-stage cerebral infarction and its effects on plasma substance P level and latent time of swallowing reflex.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Infarction; Cilostazol; Deglutition; Female; Humans | 2013 |
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Cilostazol; Diabetes Complications; Double-Blind Method; | 2008 |
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cilostazol; Double-Blind Method; Female; Follow-Up Studie | 2010 |
Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report.
Topics: Aged; Cerebral Infarction; Cilostazol; Female; Humans; Incidence; Male; Middle Aged; Phosphodiestera | 2011 |
Antithrombotic therapy for prevention of pneumonia.
Topics: Aged; Cerebral Infarction; Cilostazol; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Pn | 2001 |
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
Topics: Aged; Asian People; Carotid Arteries; Cerebral Infarction; Cilostazol; Diabetes Mellitus, Type 2; Di | 2002 |
24 other studies available for cilostazol and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Cerebral Infarction; Cilostazol; C | 2021 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Cerebral Infarction; Chi-Square Distribution; Cilostaz | 2018 |
Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction.
Topics: Acute Disease; Aged; Cerebral Infarction; Chi-Square Distribution; Cilostazol; Disability Evaluation | 2018 |
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Cerebral Infarction; Cilostazol; Dose-Response Relationship, Drug; F | 2019 |
Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.
Topics: Aged; Cell Adhesion Molecules; Cerebral Infarction; Cilostazol; Cytochrome P-450 CYP2C19; Cytochrome | 2018 |
A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease.
Topics: Adult; Aspirin; Cerebral Angiography; Cerebral Infarction; Cilostazol; Diffusion Magnetic Resonance | 2019 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Cerebral Infarction; Child, Preschool; Cilo | 2009 |
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
Topics: Animals; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Disease Models | 2009 |
Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebral Infarction; Cilostazol; Disability | 2009 |
[Combination of percutaneous balloon angioplasty and aggressive medical intervention improves symptomatic basilar artery stenosis with a tortuous access route: case report].
Topics: Aged; Angioplasty, Balloon; Cerebral Angiography; Cerebral Infarction; Cilostazol; Eicosapentaenoic | 2010 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol.
Topics: Animals; Aspirin; Biomarkers; Cerebral Infarction; Cilostazol; Clopidogrel; Hippocampus; Male; Nerve | 2012 |
Efficacy of cilostazol in preventing aspiration pneumonia in acute cerebral infarction.
Topics: Activities of Daily Living; Acute Disease; Adult; Aged; Aged, 80 and over; Cerebral Infarction; Cilo | 2013 |
[Application of magnetic resonance imaging in drug discovery and development].
Topics: Animals; Brain; Cerebral Infarction; Cilostazol; Drug Discovery; Magnetic Resonance Imaging; Mice; M | 2012 |
Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction.
Topics: Aged; Aspirin; Case-Control Studies; Cerebral Infarction; Cilostazol; Cost-Benefit Analysis; Health | 2006 |
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Chronic Disease; Cilostazol; Female; Follow-Up Studies; H | 2006 |
Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Brain Ischemia; Caspase 3; Cerebral Infarction; Chemot | 2007 |
Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation.
Topics: Aged; Carotid Arteries; Cerebral Infarction; Cerebrovascular Circulation; Chronic Disease; Cilostazo | 2000 |
Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication.
Topics: Aged; Azoles; Blood Pressure; Carotid Arteries; Cerebral Infarction; Cerebrovascular Circulation; Ci | 1990 |
Effect of cilostazol on experimental cerebral infarction in rabbits.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Azoles; Brain; Cerebral Infarction; Cilostazo | 1986 |
Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
Topics: Aged; Azoles; Cerebral Infarction; Cerebrovascular Circulation; Chronic Disease; Cilostazol; Female; | 1985 |